The logical extension of the committee's claim is that the government should not fund anything today on the basis of a hypothetical risk of higher prices for superior therapies in the future. Besides being asinine, it also belies the reality of a committee and policy framework that is remarkably effective at lowering prices.
Advisory committees might live to regret their increasing role as policy advisors
March 18, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
Todd Stephenson confirmed on ACT list for New Zealand election
September 14, 2026 - - Latest News -
Scandal-hit KPMG still holds $37 million in health department work
September 14, 2026 - - Latest News -
Canberra details tax changes with limited concessions for some innovators
September 14, 2026 - - Latest News -
The 'Dispatched' Week in Review Podcast - 11 September
September 11, 2026 - - Podcast -
Rare genetic motor neurone disease treatment finally reaches Australian patients
September 11, 2026 - - Latest News -
NSW pharmacists to deliver all childhood vaccines and treat more conditions under reforms
September 11, 2026 - - Latest News -
AI Health Summit 2026
September 10, 2026 - - Summit
